| Susan E Pearson, MD | |
|
1421 Premier Dr, Mankato, MN 56001-6076 | |
| (507) 624-1811 | |
| Not Available |
| Full Name | Susan E Pearson |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 1421 Premier Dr, Mankato, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821072703 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 42347 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mankato Clinic Ltd | 5597677955 | 201 |
News Archive
Being aware of our surroundings is a fundamental aspect of our existence. But what in our biological makeup determines how we access and interpret the endless stream of information around us?
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
› Verified 9 days ago
| Entity Name | Mankato Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629044029 PECOS PAC ID: 5597677955 Enrollment ID: O20031104000231 |
News Archive
Being aware of our surroundings is a fundamental aspect of our existence. But what in our biological makeup determines how we access and interpret the endless stream of information around us?
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
Being aware of our surroundings is a fundamental aspect of our existence. But what in our biological makeup determines how we access and interpret the endless stream of information around us?
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan E Pearson, MD 1421 Premier Dr, Mankato, MN 56001-6076 Ph: (507) 625-1811 | Susan E Pearson, MD 1421 Premier Dr, Mankato, MN 56001-6076 Ph: (507) 624-1811 |
News Archive
Being aware of our surroundings is a fundamental aspect of our existence. But what in our biological makeup determines how we access and interpret the endless stream of information around us?
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
› Verified 9 days ago
Grace Nimat Khouri, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1230 E. Main Street, Mankato Clinic, Ltd, Mankato, MN 56002 Phone: 507-625-1811 Fax: 952-843-4301 | |
Dr. Kaveh Karimnejad, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-625-4031 | |
Fareeda Taher Nazer Hussain, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-594-4700 | |
Mark G Cardamone-rayner, Otolaryngology Medicare: Medicare Enrolled Practice Location: 1015 Marsh St, Mankato, MN 56001 Phone: 507-389-4700 | |
Willard James Michalski, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 112 Beech Street, Mankato, MN 56001 Phone: 507-625-1589 |